| Entries |
| Document | Title | Date |
|---|
| 20080255176 | QUINOLINE DERIVATIVES - The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. | 10-16-2008 |
| 20080262017 | Sugar-Free Storage-Stable Antihistaminic Syrups - New and improved storage-stable sugar-free antihistaminic syrups are disclosed. | 10-23-2008 |
| 20080262018 | Treating allergic and inflammatory conditions - A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed. | 10-23-2008 |
| 20080269273 | TREATMENT METHOD - Methods of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition or cardiovascular disease by administrating an effective amount of loratadine, in combination with an effective amount of montelukast, for such treating and/or preventing are disclosed. | 10-30-2008 |
| 20080280938 | Screening Method - The present invention provides a medicament for preventing/treating cancer, comprising a tacrine compound, or a compound promoting the binding between the tacrine compound and a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1. | 11-13-2008 |
| 20080287481 | PROCESS FOR THE PREPARATION OF DESLORATADINE POLYMORPH MIXTURES - The present application provides a process for the preparation of mixture of polymorphic Form I and Form II of desloratadine in any desired ratio. | 11-20-2008 |
| 20080318996 | 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor - The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R | 12-25-2008 |
| 20090082385 | DEUTERIUM-ENRICHED DESLORATIDINE - The present application describes deuterium-enriched desloratadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
| 20090124651 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy. | 05-14-2009 |
| 20090137620 | USE OF GALLIUM(III) COMPLEXES FOR THE TREATMENT OF MELANOMAS - The invention relates to the use of gallium (III) complexes for the treatment of melanomas. | 05-28-2009 |
| 20090182002 | Tyrosine kinase inhibitors - This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl- | 07-16-2009 |
| 20090197907 | NOVEL CRYSTALLINE FORM OF RUPATADINE FREE BASE - The present invention relates to a novel crystalline form of rupatadine free base, process for its preparation and to a pharmaceutical composition containing it. In accordance with the present invention rupatadine is suspended in n-hexane, n-heptane, cyclohexane, diethyl ether or diisopropyl ether, stirred for at least 1 hour, filtered the solid and dried to give crystalline rupatadine form-B. The isolation of novel rupatadine free base as crystalline form-B may be useful as a purification of rupatadine or a salt thereof. | 08-06-2009 |
| 20090197908 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met - The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 08-06-2009 |
| 20090203726 | SUBSTITUTED TETRAHYDROQUINOLINES AS ANTIBACTERIAL AGENTS - A method of treating a subject for a bacterial infection includes administering to a subject in need of treatment for a bacterial infection an effective amount of a compound represented by structural formula (I-a), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. | 08-13-2009 |
| 20090203727 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION - The present invention relates to a pharmaceutical composition including loratadine or a pharmaceutically acceptable form thereof, and phenylephrine or a pharmaceutically acceptable form thereof, for treating upper respiratory/mucosal congestion, optionally by administering to a patient four times a day. | 08-13-2009 |
| 20090215811 | Novel Pharmaceutical Composition and Its Use in a Method For Treatment of Patients With Upper Respiratory Mucosal Congestion - The present invention relates to a pharmaceutical composition including loratidine, its use in the treatment of upper respiratory mucosal congestion and a method of administration of the composition. Particularly, though not exclusively, the invention relates to a pharmaceutical composition including loratidine in an amount suitable for administration a maximum of 4 times a day, and a second active that is a hydroxyl-α-[(methylamino) methyl]-benzenemethanol, such 3-hydroxyl-α-[(methylamino) methyl]-benzenemethanol (phenylephrine), or salt thereof. | 08-27-2009 |
| 20090221624 | 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS - This invention is directed to aminoquinoline compounds, pharmaceutical compositions of such compounds, kits comprising such compounds, and uses of such compounds for preparing medicaments and treating virus-related conditions in animals. | 09-03-2009 |
| 20090270440 | BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS - The invention relates to the use of N,N′-dihydroxyamidine (I), N,N′-dihydroxyamidine ether (II), N,N′-dihydroxyamidine diether (III), N,N′-dihydroxyamidine ester (IV), N,N′-dihydroxyamidine diester (V) or 4-hydroxy-1,2,4-oxadiazoline (VI) of the formulae cited above, wherein R represents hydrogen, an alkyl and/or aryl radical, as a substitute for an amidine function of a medicament for improving the bioavailability of the medicament. | 10-29-2009 |
| 20100016348 | ORALLY DISINTEGRATIVE DOSAGE FORM - The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C. | 01-21-2010 |
| 20100022576 | STABLE AND BIOAVAILABLE FORMULATIONS AND A NOVEL FORM OF DESLORATADINE - An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis, chronic idiopathic urticaria, asthma and other similar diseases. The compositions are formulated such as to provide protection to the drug from acidic excipients. The compositions of the present invention comprise desloratadine intimately mixed with hydrogenated vegetable oil and certain other excipients including acidic excipients. | 01-28-2010 |
| 20100022577 | DRY SYRUP CONTAINING LORATADINE - Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar. | 01-28-2010 |
| 20100160366 | TREATMENT METHOD - Methods of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition or cardiovascular disease by administrating an effective amount of loratadine, in combination with an effective amount of montelukast, for such treating and/or preventing are disclosed. | 06-24-2010 |
| 20100216831 | DESLORATADINE CRYSTALLINE FORMS MIXTURES HAVING A LOW LEVEL OF RESIDUAL SOLVENTS - Provided are desloratadine mixtures, comprising a low level of residual solvents and processes for the preparation thereof. | 08-26-2010 |
| 20100234414 | Use of Loratadine 10mg for the prevention of upper respiratory inflammation/sinus infections caused from exposure to bacteria and viruses on airplane flights - The invention relates to the use of Loratadine 10 mg prior to flying to prevent upper respiratory inflammation and sinus infections caused from exposure to bacteria and viruses while flying. People are packed together in airplanes, which has dry and polluted air. Flying is one of the more common places to pick up cold viruses and airborne bacteria. Use of Loratadine 10 mg before the plane takes off to shrink the nasal lining helps prevent susceptibility to bacteria and viruses. | 09-16-2010 |
| 20100261748 | STABLE LORATADINE SPILL RESISTANT FORMULATION - The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension. | 10-14-2010 |
| 20110071184 | MANUFACTURE OF TABLET IN A DIE UTILIZING RADIOFREQUENCY ENERGY AND MELTABLE BINDER - The present invention features a process for making a tablet by (i) compacting a powder blend in a die to form a tablet shape, wherein the powder blend contains a pharmaceutically active agent and a meltable binder and (ii) applying radiofrequency energy to the tablet shape for a sufficient period of time to soften or melt the binder within said tablet shape to form the tablet. | 03-24-2011 |
| 20110071185 | MANUFACTURE OF TABLET IN A DIE UTILIZING POWDER BLEND CONTAINING WATER-CONTAINING MATERIAL - The present invention features the present invention features a process for making a tablet by compacting a powder blend in a die platen to form a tablet shape, wherein the powder blend includes a pharmaceutically active agent and a water-containing material, and applying energy to the tablet shape for a sufficient period of time to heat the water-containing material within the tablet shape above its dehydration temperature to form the tablet. | 03-24-2011 |
| 20110144146 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor - The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I | 06-16-2011 |
| 20110144147 | INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHRACENEDIONE DERIVATIVE WITH ANTI-TUMORAL ACTIVITY - Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride. | 06-16-2011 |
| 20110319441 | MANUFACTURE OF VARIABLE DENSITY DOSAGE FORMS UTILIZING RADIOFREQUENCY ENERGY - The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said major face of the tablet is at least about 10% greater than the peak penetration resistance at the center of said major face; and (ii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds, and a machine and method for manufacture of such tablet. | 12-29-2011 |
| 20120010233 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE - Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel. | 01-12-2012 |
| 20120022094 | PHARMACEUTICAL FORMULATIONS - New and improved antihistaminic syrups are disclosed. | 01-26-2012 |
| 20120041018 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR - Octahydrobenzoisoquinoline modulators of dopamine receptors are described herein. Methods for using octahydrobenzoisoquinoline modulators of dopamine receptors in the treatment of dopamine dysfunction are also described herein. | 02-16-2012 |
| 20120077836 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF - Disclosed are pharmaceutical compositions and methods for the administration of (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol or a pharmaceutically acceptable salt thereof and related compounds for the treatment of neurological disorder such as Parkinson's disease and restless leg syndrome. | 03-29-2012 |
| 20120142723 | ACE2 ACTIVATOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury. | 06-07-2012 |
| 20120157488 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE - The present invention relates to compounds defined by formula I | 06-21-2012 |
| 20120157489 | TREATMENT OF ENDOMETRIOSIS - A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis. | 06-21-2012 |
| 20120245194 | SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION - The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-alpha.4 interaction. The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition. | 09-27-2012 |
| 20130203799 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 08-08-2013 |
| 20130274283 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS - Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided. | 10-17-2013 |
| 20130303564 | METHOD FOR TREATING A NEURODEGENERATIVE DISORDER - Provided herein are methods and materials for treating neurodegenerative disorders. The methods may use inhibitors of small G-proteins, such as p21 | 11-14-2013 |
| 20140088134 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION - A pharmaceutical composition comprises a solution having a pH of from 5 to 7.5, including loratadine and/or desloratadine. The composition is suitable for treatment of e.g. allergic rhinitis and allergic conjunctivitis. | 03-27-2014 |
| 20140194460 | TREATMENT OF ENDOMETRIOSIS - A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis. | 07-10-2014 |
| 20140249174 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE - The present invention relates to compounds defined by formula I | 09-04-2014 |
| 20140256765 | TRANSMUCOSAL DRUG DELIVERY SYSTEM - Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH. | 09-11-2014 |
| 20150018381 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 01-15-2015 |
| 20150018382 | Use of Rupatadine in the Manufacture of Pharmaceutical Composition for Treating Chronic Obstructive Pulmonary Disease - Disclosed is the use of rupatadine in the manufacture of pharmaceutical composition for preventing or treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease. The new medicament, i.e. rupatadine, for treating chronic obstructive pulmonary disease is obvious in therapeutic effects, and low in toxic and side effects, and safe in use in the aspects of treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease. | 01-15-2015 |
| 20150073010 | Medicament For The Treatment Of Endometriosis - The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis. | 03-12-2015 |
| 20160031899 | SHIP1 MODULATORS AND METHODS RELATED THERETO - Compounds of formula (II): wherein A, R | 02-04-2016 |
| 20160151279 | SEMI-SOLID CHEWABLE DOSAGE FORM FOR OVER-THE-COUNTER MEDICATIONS AND METHOD FOR PRODUCING SAME | 06-02-2016 |
| 20160166557 | ANTIVIRAL AGENTS | 06-16-2016 |
